Peter Hillmen Selected Research

fludarabine

1/2022	Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors.
11/2018	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
2/2016	The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.
8/2015	Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
4/2014	Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.
5/2012	Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
6/2011	A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
4/2010	Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
4/2005	Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.
1/2004	Future prospects for fludarabine-containing regimens in the treatment of hematological cancers.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Hillmen Research Topics

Disease

76	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 01/2002
26	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 09/2022 - 05/2002
24	Hemolysis 09/2022 - 01/2002
19	Neoplasms (Cancer) 11/2021 - 01/2002
15	Residual Neoplasm 11/2021 - 03/2004
14	Disease Progression 01/2022 - 03/2004
14	Infections 11/2021 - 01/2002
13	Fatigue 09/2022 - 09/2006
9	Diarrhea 01/2021 - 07/2014
8	Thrombosis (Thrombus) 01/2020 - 11/2003
8	Neutropenia 01/2019 - 05/2015
6	Atrial Fibrillation 11/2021 - 03/2015
6	Hemorrhage 01/2021 - 11/2003
6	Lymphocytosis 01/2020 - 12/2007
5	Anemia 09/2022 - 04/2005
5	Hypertension (High Blood Pressure) 12/2019 - 05/2010
5	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2018 - 04/2005
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 08/2003
4	Chronic Disease (Chronic Diseases) 01/2021 - 09/2006
4	Cough 01/2019 - 07/2014
4	Nausea 12/2018 - 12/2007
4	Pulmonary Hypertension 07/2013 - 04/2005
3	Abdominal Pain (Pain, Abdominal) 09/2022 - 05/2007
3	Hemoglobinuria 09/2022 - 02/2004
3	Leukemia 12/2020 - 02/2006
3	Fever (Fevers) 12/2018 - 07/2014
3	Cytopenia 12/2013 - 01/2002
2	Deglutition Disorders (Dysphagia) 09/2022 - 05/2007
2	Erectile Dysfunction 09/2022 - 05/2007
2	Headache (Headaches) 01/2021 - 01/2019
2	Aplastic Anemia (Anemia, Hypoplastic) 11/2019 - 01/2018
2	B-Cell Lymphoma (Lymphoma, B Cell) 05/2019 - 01/2018
2	Pneumonia (Pneumonitis) 01/2019 - 01/2017
2	Hematologic Neoplasms (Hematological Malignancy) 12/2018 - 03/2002
2	Tumor Lysis Syndrome 12/2018 - 03/2018
2	Febrile Neutropenia 03/2018 - 01/2017
2	Thrombocytopenia (Thrombopenia) 01/2017 - 02/2008
2	Lymphadenopathy 01/2017 - 04/2010
2	Vomiting 12/2015 - 12/2007
2	Lymphoid Leukemia 07/2014 - 01/2004
2	Chronic Renal Insufficiency 07/2013 - 08/2010
1	Dyspnea (Shortness of Breath) 09/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2021
1	Atrial Flutter (Flutter, Atrial) 11/2021
1	Injection Site Reaction 01/2021
1	COVID-19 10/2020
1	Spontaneous Remission 01/2020

Drug/Important Bio-Agent (IBA)

35	ibrutinibIBA 01/2022 - 07/2014
26	eculizumab FDA Link 09/2022 - 02/2004
18	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 01/2016
16	Rituximab (Mabthera)FDA Link 01/2022 - 02/2004
13	Complement System Proteins (Complement)IBA 01/2021 - 01/2002
13	Alemtuzumab (Campath)FDA Link 01/2017 - 01/2002
12	fludarabineIBA 01/2022 - 03/2002
10	ofatumumab FDA Link 01/2020 - 04/2010
9	Chlorambucil (Leukeran)FDA Link 01/2022 - 12/2007
9	acalabrutinibIBA 01/2022 - 01/2016
8	idelalisibIBA 01/2021 - 03/2014
7	venetoclaxIBA 12/2020 - 01/2018
5	Bendamustine Hydrochloride FDA Link 01/2022 - 01/2017
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 04/2005
5	Glycosylphosphatidylinositols (Glycosyl-Phosphatidylinositol)IBA 08/2021 - 05/2002
5	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 07/2013 - 10/2005
4	Biological ProductsIBA 01/2020 - 01/2004
4	Proteins (Proteins, Gene)FDA Link 03/2018 - 01/2002
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 08/2012 - 04/2005
4	Monoclonal AntibodiesIBA 06/2011 - 03/2002
4	Complement Inactivating AgentsIBA 08/2010 - 09/2006
3	zanubrutinibIBA 01/2022 - 04/2020
3	serum P-component (CIt)IBA 10/2021 - 11/2018
3	GPI-Linked ProteinsIBA 08/2021 - 01/2004
3	Pharmaceutical PreparationsIBA 01/2021 - 10/2016
3	Hemoglobins (Hemoglobin)IBA 01/2021 - 04/2005
3	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 11/2019 - 12/2007
2	TESIBA 09/2022 - 07/2013
2	Transaminases (Aminotransferases)IBA 12/2020 - 01/2019
2	duvelisibIBA 01/2020 - 12/2018
2	Biomarkers (Surrogate Marker)IBA 05/2019 - 08/2012
2	AntibodiesIBA 03/2016 - 01/2004
2	Lenalidomide (CC 5013)FDA Link 01/2016 - 03/2012
2	pro-brain natriuretic peptide (1-76)IBA 08/2012 - 05/2010
2	Brain Natriuretic Peptide (Natrecor)FDA Link 08/2012 - 05/2010
2	Warfarin (Coumadin)FDA LinkGeneric 06/2011 - 11/2003
2	Alkylating AgentsIBA 09/2007 - 05/2002
2	purineIBA 01/2004 - 08/2003
1	Indicators and Reagents (Reagents)IBA 11/2021
1	Peptides (Polypeptides)IBA 01/2021
1	ravulizumabIBA 01/2021
1	pegcetacoplanIBA 01/2021
1	forodesineIBA 12/2020
1	deoxyguanosine triphosphate (dGTP)IBA 12/2020
1	FibrinIBA 01/2020
1	6- (1H- indazol- 6- yl)- N- (4- morpholinophenyl)imidazo(1,2- a)pyrazin- 8- amineIBA 01/2020
1	tirabrutinibIBA 01/2020
1	Immunoglobulin Variable RegionIBA 01/2020

Therapy/Procedure

46	Therapeutics 01/2022 - 03/2002
8	Drug Therapy (Chemotherapy) 11/2019 - 03/2002
3	Aftercare (After-Treatment) 01/2017 - 05/2002
2	Blood Transfusion (Blood Transfusions) 12/2013 - 01/2009
1	Precision Medicine 12/2020